LGND
LIGAND PHARMACEUTICALS INC
Key Financials
Revenue
$268.1M
↑ 60.4%
Net Income
$124.5M
↑ 3186.6%
Operating Income
$41.0M
↑ 281.4%
EPS (Diluted)
$6.13
↑ 2886.4%
Total Liabilities
$543.4M
↑ 388.1%
Total Assets
$1.6B
↑ 65.7%
Shareholders' Equity
$1.0B
↑ 22.5%
Long-term Debt
$27.5M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 7/1/2026 | View on SEC |
| 8-K | 6/25/2026 | View on SEC |
| 8-K | 6/22/2026 | View on SEC |
| 4 | 6/18/2026 | View on SEC |
| 144 | 6/16/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 144 | 6/12/2026 | View on SEC |
| 144 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LGND |
| Company Name | LIGAND PHARMACEUTICALS INC |
| CIK | 886163 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-550-7500 |